Oral Cancer Treatment Costs in Greece and the Effect of Advanced Disease

DSpace/Manakin Repository

Oral Cancer Treatment Costs in Greece and the Effect of Advanced Disease

Citable link to this page

 

 
Title: Oral Cancer Treatment Costs in Greece and the Effect of Advanced Disease
Author: Andreopoulos, Nikos; Katsikeris, Nikos; Zavras, Dimitrios; Cartsos, Vassiliki; Vamvakidis, Athanasios; Zavras, Athanasios I.

Note: Order does not necessarily reflect citation order of authors.

Citation: Zavras, Athanasios, Nikos Andreopoulos, Nikos Katsikeris, Dimitrios Zavras, Vassiliki Cartsos, and Athanasios Vamvakidis. 2002. Oral cancer treatment costs in Greece and the effect of advanced disease. BMC Public Health 2:12.
Full Text & Related Files:
Abstract: Background: The main purpose of the study was to quantify the direct costs of oral cancer treatment to the healthcare system of Greece. Another aim was to identify factors that affect costs and potential cost reduction items. More specifically, we examined the relationship between stage of disease, modality of treatment and total direct costs. Methods: The medical records and clinic files of the Oral and Maxillofacial Clinic of the Athens General Hospital "Genimatas" were abstracted to investigate clinical treatment characteristics, including length of hospitalization, modes of treatment, stage of disease etc. Records of 95 patients with oral squamous cell carcinoma (OSSC), with at least six months of follow-up, were examined. The clinical data was then used to calculate actual direct costs, based on 2001 market values. Results: The mean total direct costs for OSSC treatment estimated at euro 8,450 or approximately US$ 7,450. Costs depended on the stage of the disease, with significant increases in stages III and IV, as compared with stages I and II (p < 0.05). Multi-modality treatment applied mainly to patients in stages III and IV was the factor that affected the cost. Disease stage was also associated with the total duration of hospitalization (p < 0.05). Conclusions: The clinical management of advanced oral cancer is strongly associated with higher costs. Although the ideal would be to prevent cancer, the combination of high-risk screening, early diagnosis and early treatment seems the most efficient way to reduce costs, and most importantly, prolong life.
Published Version: doi://10.1186/1471-2458-2-12
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC117788/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4514594
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters